Photo of George L. Mutter,  MD

George L. Mutter, MD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 732-6096
Fax: (617) 738-6996


gmutter@rics.bwh.harvard.edu

George L. Mutter, MD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Professor, Pathology, Harvard Medical School
  • Associate Pathologist, Pathology, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

The molecular biology of gynecologic cancers is the focus of my lab, primarily endometrial carcinoma. We have developed molecular assays for premalignant disease, and used these to revise routine diagnostic practices and study the natural history of early carcinogenesis.

Publications

Powered by Harvard Catalyst
  • Yang EJ, Mutter GL. Biomarker resolution of uterine smooth muscle tumor necrosis as benign vs malignant. Mod Pathol 2015. PubMed
  • Nagymanyoki Z, Mutter GL, Hornick JL, Cibas ES. ARID1A is a useful marker of malignancy in peritoneal washings for endometrial carcinoma. Cancer Cytopathol 2015. PubMed
  • Mutter GL, Monte NM, Neuberg D, Ferenczy A, Eng C. Emergence, involution, and progression to carcinoma of mutant clones in normal endometrial tissues. Cancer Res 2014. PubMed
  • Parra-Herran CE, Monte NM, Mutter GL. Endometrial intraepithelial neoplasia with secretory differentiation: diagnostic features and underlying mechanisms. Mod Pathol 2013. PubMed
  • Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, Higgins R, Zaino R, Mutter GL, . Management of endometrial precancers. Obstet Gynecol 2012; 120:1160-75. PubMed
  • Quick CM, Laury AR, Monte NM, Mutter GL. Utility of PAX2 as a marker for diagnosis of endometrial intraepithelial neoplasia. Am J Clin Pathol 2012; 138:678-84. PubMed
  • Huang EC, Mutter GL, Crum CP, Nucci MR. Clinical outcome in diagnostically ambiguous foci of 'gland crowding' in the endometrium. Mod Pathol 2010; 23:1486-91. PubMed
  • Roh MH, Yassin Y, Miron A, Mehra KK, Mehrad M, Monte NM, Mutter GL, Nucci MR, Ning G, Mckeon FD, Hirsch MS, Wa X, Crum CP. High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod Pathol 2010; 23:1316-24. PubMed
  • Chen EY, Mehra K, Mehrad M, Ning G, Miron A, Mutter GL, Monte N, Quade BJ, McKeon FD, Yassin Y, Xian W, Crum CP. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol 2010; 222:110-6. PubMed
  • Monte NM, Webster KA, Neuberg D, Dressler GR, Mutter GL. Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer. Cancer Res 2010; 70:6225-32. PubMed
  • Jarboe EA,Miron A,Carlson JW,Hirsch MS,Kindelberger D,Mutter GL,Crum CP,Nucci MR. Coexisting Intraepithelial Serous Carcinomas of the Endometrium and Fallopian Tube: Frequency and Potential Significance. Int J Gynecol Pathol 2009; 28:308-15. PubMed
  • Lin MC,Burkholder KA,Viswanathan AN,Neuberg D,Mutter GL. Involution of latent endometrial precancers by hormonal and nonhormonal mechanisms. Cancer 2009; 115:2111-8. PubMed
  • Jarboe EA, S Pizer E, Miron A, Monte N, Mutter GL, Crum CP. Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. Mod Pathol 2009; 22:345-50. PubMed
  • Ioffe OB,Zaino RJ,Mutter GL. Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator. Mod Pathol 2009; 22:450-9. PubMed
  • Lin MC,Lomo L,Baak JP,Eng C,Ince TA,Crum CP,Mutter GL. Squamous morules are functionally inert elements of premalignant endometrial neoplasia. Mod Pathol 2009; 22:167-74. PubMed
  • Lacey JV Jr,Mutter GL,Nucci MR,Ronnett BM,Ioffe OB,Rush BB,Glass AG,Richesson DA,Chatterjee N,Langholz B,Sherman ME. Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies. Cancer 2008; 113:2073-81. PubMed
  • Lomo L,Nucci MR,Lee KR,Lin MC,Hirsch MS,Crum CP,Mutter GL. Histologic and immunohistochemical decision-making in endometrial adenocarcinoma. Mod Pathol 2008; 21:937-42. PubMed
  • Lacey JV Jr,Mutter GL,Ronnett BM,Ioffe OB,Duggan MA,Rush BB,Glass AG,Richesson DA,Chatterjee N,Langholz B,Sherman ME. PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Res 2008; 68:6014-20. PubMed
  • Mutter GL, Kauderer J, Baak JP, Alberts D. Biopsy histomorphometry predicts uterine myoinvasion by endometrial carcinoma: a Gynecologic Oncology Group study. Hum Pathol 2008; 39:866-74. PubMed
  • Mutter GL, Bergeron C, Deligdisch L, Ferenczy A, Glant M, Merino M, Williams AR, Blithe DL. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008; 21:591-8. PubMed
  • Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL, Platzer P, Eng C. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 2007; 357:2543-51. PubMed
  • Mutter GL, Zaino RJ, Baak JP, Bentley RC, Robboy SJ. Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. Int J Gynecol Pathol 2007; 26:103-14. PubMed
  • Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006; 24:4783-91. PubMed
  • . Regression of latent endometrial precancers by progestin infiltrated intrauterine device. Cancer Res 2006; 66:5613-7. PubMed
  • Berman JJ, Albores-Saavedra J, Bostwick D, Delellis R, Eble J, Hamilton SR, Hruban RH, Mutter GL, Page D, Rohan T, Travis W, Henson DE. Precancer: a conceptual working definition -- results of a Consensus Conference. Cancer Detect Prev 2006; 30:387-94. PubMed
  • Lomo L, Nucci MR, Lee KR, Lin MC, Hirsch MS, Crum CP, Mutter GL. Histologic and immunohistochemical decision-making in endometrial adenocarcinoma. Mod Pathol 2008; 21:937-42.
Hide